Loading...
Geron Corporation
0IV3.L•LSE
Healthcare
Medical - Pharmaceuticals
£1.48
£0.08(6.09%)
Geron Corporation (0IV3.L) Company Profile & Overview
Explore Geron Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Geron Corporation (0IV3.L) Company Profile & Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
SectorHealthcare
IndustryMedical - Pharmaceuticals
CEODawn Carter Bir
Contact Information
Company Facts
229 Employees
IPO DateJan 29, 2018
CountryUS
Actively Trading